Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NVA237 add-on to salmeterol/fluticasone in COPD
2012-002854-21Phase 3Terminated
- Sponsor
- Novartis
- Start
- Jan 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in chronic obstructive pulmonary disease (COPD) comparing Glycopyrronium bromide add-on arm with Placebo add-on arm (2 arms). Primary endpoint: Trough FEV1. Started Jan 2013; status: terminated.
02
Drugs
glycopyrronium
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on 2012-002854-21.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-002854-21.